Figure 3.

Phospholamban Ser16 (Panel A) and Thr17 (Panel B) phosphorylation in pediatric non-failing, failing, and failing hearts treated with an LVAD (F-LVAD, L) with representative Western blots normalized to GAPDH. Phospholamban Ser16 phosphorylation is significantly higher in LVAD treated hearts compared with nonfailing and failing. (*) P<0.05. PLN, phospholamban.